Alivus Life Sciences (NSE:ALIVUS) EBIT : ₹5,940 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences EBIT?

Alivus Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ₹1,856 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹5,940 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alivus Life Sciences's annualized ROC % for the quarter that ended in Dec. 2024 was 24.03%. Alivus Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 36.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alivus Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 4.58%.

Alivus Life Sciences EBIT Historical Data

The historical data trend for Alivus Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences EBIT Chart

Alivus Life Sciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

4,545.82

5,584.91

5,928.87

6,291.56

6,328.36

Alivus Life Sciences Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial															1,610.70	1,300.42	1,505.91	1,277.99	1,856.05

Competitive Comparison of Alivus Life Sciences's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alivus Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's EV-to-EBIT falls into.

Alivus Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,940 Mil.

Alivus Life Sciences (NSE:ALIVUS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alivus Life Sciences's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	7005.96 * ( 1 - 26.03% )	/	( (21564.92	+	0)	/ 1 )
=	5182.308612	/	21564.92
=	24.03 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30848.59	-	3981.65	-	( 5302.02	-	max(0, 4637.34	-	20960.58	+	5302.02	))
=	21564.92

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Alivus Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	7424.2	/	( ( (9451.24 + max(11047.19, 0))	+	(0 + max(0, 0)) )	/	1 )
=	7424.2	/	( ( 20498.43	+	0 )	/	1 )
=	7424.2	/	20498.43
=	36.22 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7751.27	+	6892.03	+	1015.26)	-	(3981.65	+	0	+	629.72)
=	11047.19

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alivus Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	5940.37	/	129697.522
	=	4.58 %

Alivus Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alivus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » EBIT

Traded in Other Exchanges

543322:India

Address

470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099

Website

https://www.alivus.com

Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines